Navigation Links
Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
Date:9/22/2007

ALLEGAN, Mich., Sept. 19 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Ciclopirox Topical Solution, 8% (Nail Lacquer). Shipments will begin immediately.

The product has been determined to be therapeutically equivalent (AT) to Sanofi Aventis US, LLC's Penlac(R) Nail Lacquer, indicated for the treatment of mild to moderate fungal infections of the fingernails and toenails. According to Wolters Kluwer data, brand sales for the last 12 months ending August, 2007 were $92 million.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Receives FDA Approval to Market Coated Fruit Nicotine Gum
2. Medicis Pharmaceutical company enters pediatric market
3. Problems Of a Growing Company
4. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
5. British company developing ‘Safer Cigarettes
6. Australian Company Gets $10 million For Developing Skin Cancer Gel
7. Elderly People Prefer The Company Of Pet Dogs
8. Ossur Acquires the U.S. Orthopaedics Company
9. Britain Approves Indian Company For Supplying Medicines
10. Drug Company Admits Knowledge Of Side Effects In Monkeys
11. Ranbaxy Expands By Acquiring A Generic Company In Belgium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... The ... Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits and ... the District of Columbia as an education tool in the war against teen drug ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated ... new solution for Emergency Departments (ED) has been added to their portfolio. Housed ... examination rooms, and with a simplified pallet of information available to the patient, ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... This report on the global interventional radiology market ... market. The report comprises an elaborate executive summary, ... of various segments and sub-segments. The research ... Primary research formed the bulk of our research ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 KEY ... for the largest share of the market in 2016 ... This dominance can be attributed to a large number ... region. (US hold the largest share in the patient ... several benefits such as reducing loss of blood during ...
(Date:12/8/2016)... , Dec. 8, 2016 Allergy ... includes products and tests that are used to ... weed, peanuts, milk, or drugs etc. in the ... by the immune system. The report on global ... prospects of the market. The report consists of ...
Breaking Medicine Technology: